Harmony Biosciences
HRMY
32.59
-0.39
-1.18%
Harmony Biosciences
US · HRMY
#2681 by market cap
Listed 2020
32.59
-0.39
-1.18%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Rating change
Piper Sandler Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Cuts Target Price to $46Market Newswire · 2026/4/22
-
Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $50Market Newswire · 2026/10/19
-
Rating change
Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $44Market Newswire · 2026/4/14
-
Rating change
Wolfe Research Initiates Harmony Biosciences(HRMY.US) With Buy Rating, Announces Target Price $60Market Newswire · 2026/8/26
-
Rating change
Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $45Market Newswire · 2026/5/8
-
Rating change
BofA Securities Maintains Harmony Biosciences(HRMY.US) With Sell Rating, Maintains Target Price $30Market Newswire · 2026/10/12
-
Rating change
A Quick Look at Today's Ratings for Harmony Biosciences(HRMY.US), With a Forecast Between $30 to $55Market Newswire · 2026/8/5
-
Rating change
Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $51Market Newswire · 2026/7/31
-
Rating change
Oppenheimer Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $72Market Newswire · 2026/4/22
-
Rating change
Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $50Market Newswire · 2026/7/28
-
Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Cuts Target Price to $49Market Newswire · 2026/10/29
-
Rating change
Deutsche Bank Maintains Harmony Biosciences(HRMY.US) With Hold Rating, Raises Target Price to $39Market Newswire · 2026/8/5
-
Rating change
Deutsche Bank Maintains Harmony Biosciences(HRMY.US) With Hold Rating, Raises Target Price to $36Market Newswire · 2026/6/30
-
H.C. Wainwright Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $55Market Newswire · 2026/11/12
-
Deutsche Bank Maintains Harmony Biosciences(HRMY.US) With Hold Rating, Raises Target Price to $42Market Newswire · 2026/10/1
-
Rating change
Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $45Market Newswire · 2026/7/16
-
Rating change
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Harmony Biosciences Holdings (HRMY) and Adlai Nortye Ltd. Sponsored ADR (ANL)TipRanks · 2026/7/16
-
Rating change
Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $51Market Newswire · 2026/10/12
-
Rating change
Goldman Sachs Upgrades Harmony Biosciences(HRMY.US) to Hold Rating, Raises Target Price to $37Market Newswire · 2026/7/17
-
UBS Maintains Harmony Biosciences(HRMY.US) With Hold Rating, Raises Target Price to $39Market Newswire · 2026/11/6
-
H.C. Wainwright Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $55Market Newswire · 2026/10/27
-
Rating change
A Quick Look at Today's Ratings for Harmony Biosciences(HRMY.US), With a Forecast Between $30 to $62Market Newswire · 2026/2/26
-
H.C. Wainwright Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $55Market Newswire · 2026/10/13
-
Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $50Market Newswire · 2026/9/24
-
Rating change
Truist Financial Maintains Harmony Biosciences(HRMY.US) With Hold RatingMarket Newswire · 2026/2/24
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:36 · For reference only, not investment advice and not tailored to your situation.
Harmony Biosciences discussion 0 comments